Genmab to Share Latest Epcoritamab Trial Results at 2024 EHA Congress

Genmab A/S (Nasdaq: GMAB) has announced the acceptance of multiple abstracts for presentation at the 2024 European Hematology Association (EHA) Congress, scheduled to take place in Madrid, Spain and virtually from June 13-16, 2024. The presentations will focus on the evaluation of epcoritamab, a subcutaneously administered T-cell engaging bispecific antibody. The data will cover the safety and efficacy of epcoritamab as both a monotherapy and in combination with other treatments across different patient populations.

The highlight of the congress will be three oral presentations showcasing novel data on epcoritamab. The first presentation will cover the pivotal and cycle 1 dose optimization cohorts of the EPCORE NHL-1 study, which evaluates epcoritamab in patients with relapsed/refractory follicular lymphoma (FL). The second presentation will discuss data from the EPCORE NHL-5 study, which investigates the combination of epcoritamab with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as a potential first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL). The third presentation will feature findings from the EPCORE CLL-1 study, which examines the efficacy of epcoritamab in patients with Richter’s transformation (RT).

All the abstracts accepted for presentation have been published and are accessible through the EHA Open Access Library. Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab, expressed enthusiasm about presenting the new data at EHA 2024. She emphasized the significant progress made in developing epcoritamab as a potential core therapy for various B-cell malignancies and highlighted the strong partnership with AbbVie in advancing this robust development program.

Epcoritamab is an IgG1-bispecific antibody, created using Genmab's proprietary DuoBody® technology, and is administered subcutaneously. The DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to target cell types, thereby eliciting an immune response. Epcoritamab binds simultaneously to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.

Epcoritamab has received regulatory approval for certain lymphoma indications in various territories. However, its use in follicular lymphoma (FL) is not yet approved in the U.S., EU, or other regions. The antibody is being co-developed by Genmab and AbbVie as part of their oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie taking charge of global commercialization.

The development of epcoritamab continues with its evaluation as both a monotherapy and in combination with other treatments across different lines of therapy in a range of hematologic malignancies. This includes four ongoing phase 3, open-label, randomized trials. These trials are investigating epcoritamab as a monotherapy for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), in combination with R-CHOP for newly diagnosed DLBCL, with rituximab and lenalidomide for R/R FL, and with rituximab and lenalidomide (R2) compared to chemotherapy for previously untreated FL.

Genmab is a global biotechnology company dedicated to improving patient lives through innovative antibody therapeutics. Over the past 25 years, the company has developed next-generation antibody technology platforms and formed over 20 strategic partnerships with biotechnology and pharmaceutical companies. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with additional locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. The company's vision for 2030 is to transform the lives of people with cancer and other serious diseases through groundbreaking antibody medicines.